Double-Blind, Placebo-Controlled, Randomized, Crossover Trial of High-Dose Methylprednisolone in Patients with Chronic Progressive Form of Multiple Sclerosis
- 1 January 1995
- journal article
- clinical trial
- Published by S. Karger AG in European Neurology
- Vol. 35 (4) , 193-198
- https://doi.org/10.1159/000117127
Abstract
A double-blind, placebo-controlled, randomized crossover trial of high-dose methylprednisolone (MP) was performed in 35 patients with a primarily chronic progressive form of multiple sclerosis as defined clinically according to Poser’s criteria. At time 0 of every course of treatment (1 g MP administered i.v. daily for 5 days followed by oral prednisone tapering over 4 days, or placebo) and at 10, 30 and 90 days thereafter, each patient underwent psychometric tests and was clinically tested according to Kurtzke’s Expanded Disability Status Scale (EDSS). The disability pattern of most patients who were treated with placebo either worsened or did not change. A statistically significant improvement (pKeywords
This publication has 0 references indexed in Scilit: